Takeda Korea said it appointed Park Kwang-kyu, also known as Kenny Park, as its new General Manager.
Takeda Korea appoints industry veteran Kwang-kyu Park as its new General Manager to drive innovation and strengthen partnerships in the pharmaceutical sector. (Credit: Takeda Korea)
Takeda Korea appoints industry veteran Kwang-kyu Park as its new General Manager to drive innovation and strengthen partnerships in the pharmaceutical sector. (Credit: Takeda Korea)
With over two decades of experience in the pharmaceutical industry, Park is recognized as an expert with strong leadership in specialty care and oncology, particularly in hematologic malignancies and immunotherapy.
Before joining Takeda Korea, Park worked in various global pharmaceutical companies, including BMS Korea, AstraZeneca Korea, and MSD Korea, where he led efforts in new drug introduction, organizational innovation, and stakeholder collaboration.
Most recently, he served as the Senior Director of Gilead Sciences Korea’s Liver Disease Business Unit.
Park holds a degree in pharmacy from Kyung Hee University and earned his MBA from Seoul National University’s Graduate School of Business.
“Takeda Korea has consistently pursued patient-centered innovation amid a rapidly evolving healthcare landscape,” said Park. “Moving forward, we will accelerate the introduction of innovative therapies and seek diverse solutions to ensure that both healthcare professionals and patients have access to optimal treatment opportunities.”
He further emphasized his commitment to strengthening collaboration with Korean biotech and pharmaceutical companies to improve the treatment environment and contribute to the sustainable development of Korea’s pharmaceutical industry.
Mahender Nayak, Senior Vice President of Growth and Emerging Markets at Takeda Pharmaceuticals expressed his confidence in Park’s leadership.
“We are thrilled to welcome Park to Takeda, especially as we advance six innovative late-stage pipeline assets,” Nayak said. “His extensive business experience and strategic leadership will be instrumental in ensuring Takeda Korea’s continued success.”
Copyright © KBR Unauthorized reproduction, redistribution prohibited
Novo Nordisk Korea announced on Wednesday that it appointed Kasper Roseeuw Poulsen as general manager, effective March 1.
Since joining Novo Nordisk in 2006, Poulsen has held key leadership positions in finance, strategy, organizational development, commercial partnerships, and operations in Europe, Latin America, and Asia Pacific.
Most recently, Poulsen served as Vice President of Finance and Operations for Novo Nordisk's Asia-Pacific (APAC) region, overseeing more than 20 countries. Previously, he was Chief Vice President (CVP) of the company's China office.
Kasper Roseeuw Poulsen, new GM of Novo Nordisk Korea
Kasper Roseeuw Poulsen, new GM of Novo Nordisk Korea
Poulsen holds a bachelor's degree in Business Administration from Aarhus University, Denmark, and completed a master's program in Finance and International Business at Aarhus Business School.
“Korea is a key market in the Asia-Pacific region and a healthcare leader with an innovative healthcare environment, and I am excited to lead Novo Nordisk Korea,” said Poulsen. “I look forward to building closer and more sustainable collaborations with Korean healthcare professionals and key healthcare partners to ensure that Novo Nordisk's leadership in chronic diseases is translated into enhanced benefits for patients.”
The former GM, Sasha Semienchuk, was promoted to CVP Marketing at Novo Nordisk China, where he will oversee commercial activities across the Chinese mainland.
Since taking office as GM of Novo Nordisk Korea in October 2022, Semienchuk has exemplified Novo Nordisk's patient-centered corporate values in the Asia-Pacific region through his exceptional leadership, the company said.
In addition to leading the supply of products in various therapeutic areas, including Wegovy (semaglutide), he contributed to fostering a corporate culture that embraces diversity and supports mutual growth between the company and its employees, leading to Novo Nordisk Korea’s recognition as a “Great Place to Work” and “Best Worlplace for Women” for two consecutive years.
Furthermore, Semienchuk signed several global clinical trial collaboration memoranda of understanding with major Korean medical institutions to develop new drugs in the field of chronic diseases and established strategic partnerships with organizations such as Kakao Healthcare, Korea Health Industry Development Institute (KHIDI), and the Seoul Metropolitan Government, successfully advancing various collaborative projects to develop the domestic chronic disease management ecosystem.
Related articles
Korean doctors say obesity treatment matters—so why aren’t they prescribing?
Sam Chun Dang Pharm begins bioequivalence study for oral semaglutide
Wegovy’s success in Korea hinges on tackling misuse and cost barriers: experts
Novo Nordisk Korea signs MOU with SNUBH to advance future medical technologies
[Top 10 Healthcare News in 2024 ③] Wegovy shakes up Korea's obesity market amid illegal trade and soaring demand
Novo Nordisk Korea partners with SNUH to expand global clinical trials participation
Korea to restrict telemedicine prescriptions for Wegovy starting Dec. 2
Novo Nordisk hosts World Diabetes Day 2024 symposium
Novo Nordisk joins forces with Seoul to boost health equity through 'Cities for Better Health' initiative
Kim Chan-hyuk kch@docdocdoc.co.kr
[See Other Articles](/news/articleList.html?sc_area=I&sc_word=Kim Chan-hyuk&view_type=sm)
Copyright © KBR Unauthorized reproduction, redistribution prohibited